Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!

AstraZeneca – Cash Concerns Loom As Spending Continues

By Anna Peel. Originally published at ValueWalk.

AstraZeneca JPMorgan S&P 500 Fortive Petrofac Alphabet Amazon Chevron Phoenix Group Sprouts Farmers Markets Vistry 52-Week Lows Financial Markets Shell Buy Signals earnings NYMARKET:SPY worst performing large cap stocks in 2021

AstraZeneca plc (LON:AZN)’s first quarter revenue beat expectations and rose 60% to $11.4bn ignoring the impact of exchange rates. This was driven by growth in most categories, the contribution of Alexion’s portfolio of products and Covid-vaccine contracts.

Cash profits (EBITDA) fell 16% to $2.2bn, lower than market expectations. This reflected costs associated with the Alexion acquisition, including a $1.2bn charge related to the revaluation of Alexion’s inventory. A 36% increase in Research and development costs also contributed to the decline.

Q1 2022 hedge fund letters, conferences and more

The group continues to expect full year revenue to rise in the high teens and earnings per share to increase by a mid-to-high twenties percentage.

Shares were broadly flat following the announcement.

AstraZeneca’s Earnings

Laura Hoy, Equity Analyst at Hargreaves Lansdown:

“AstraZeneca’s product portfolio’s had a boost from its Alexion acquisition and that’s helped the group surpass revenue expectations. But the new drugs are still just a drop in AZN’s massive revenue bucket, with the entire portfolio contribution roughly $400m more than the group’s lung cancer drug, Tagrisso, on its own. The cost to bring these medicines into the fold now make up a substantial portion of the group’s debt pile and weighed significantly on profits this quarter, though.

Still, you’ve got to be able to see the forest through the trees and AZN’s got its eye on the future. Rare disease drugs are less likely to see their sales cannibalised by generics once their patents run out, so this was a smart long-term move. But we’re slightly concerned that the group could be overshooting just how difficult it will be to dig itself out from under its mounting debt pile. The group announced plans to build a new research and development centre alongside results. This will only increase the ballooning demands on the group’s cash.”


About Hargreaves Lansdown

Almost 1.7 million clients trust us with £141.2 billion (as at 31 December 2021), making us the UK’s number one platform for private investors. More than 98% of client activity is done through our digital channels and over 600,000 access our mobile app each month.

Updated on

Sign up for ValueWalk’s free newsletter here.


Do you know someone who would benefit from this information? We can send your friend a strictly confidential, one-time email telling them about this information. Your privacy and your friend's privacy is your business... no spam! Click here and tell a friend!





You must be logged in to make a comment.
You can sign up for a membership or get a FREE Daily News membership or log in

Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!